Maintain BUY with a revised TP of Rs 1,584 (22x FY20E EPS). After the acquisition of Unichems domestic business, Torrent Pharma (TRP) has become the fifth largest pharmaceutical company in India. This was TRPs first result with the entire three months revenues of Unichem India portfolio. Top line grew 20%YoY to Rs 17.2bn, EBITDA Margin came in at 21.1% and PAT was up by 11%YoY.